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1. ENVIRONMENTAL CONTAMINATION WITH
CHROMIUM
ThreethermodynamicallystableCrforms,Cr(0),Cr(III),and
Cr(VI), are used commercially and are present in the environ-
ment.Cr(0)isfoundalmostexclusivelyinitsmetallicform,most
commonly as a component of iron-based alloys such as stainless
steel. Only Cr(VI), but not Cr(0) or Cr(III), has been shown to
cause cancers in laboratory animals and occupationally exposed
workers.
1 3 Environmental pollution with various forms of Cr
results from its numerous uses in the chemical industry, produc-
tion of dyes, wood preservation, leather tanning, chrome plating,
manufacturingofvariousalloys,andmanyotherapplicationsand
products.
1,2Stainlesssteelcontainsupto20%Crbyweightandis
the highest volume product containing this metal. The magni-
tude of Cr utilization is also evident from the estimated occupa-
tionalexposurebymorethan500,000workersintheU.S.alone.
3
Incineration and emissions from cars create ambient pollution
with small Cr(VI)- and Cr(III)-containing particles, which leads
tolow-levelinhalationexposuresbylargesegmentsofthegeneral
population and increases Cr levels in surface waters. The most
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ABSTRACT:Drinking water suppliesinmanygeographicareas containchromiuminthe
+3 and +6 oxidation states. Public health concerns are centered on the presence of
hexavalent Cr that is classiﬁed as a known human carcinogen via inhalation. Cr(VI) has
high environmental mobility and can originate from anthropogenic and natural sources.
Acidic environments with high organic content promote the reduction of Cr(VI) to
nontoxic Cr(III). The opposite process of Cr(VI) formation from Cr(III) also occurs,
particularly in the presence of common minerals containing Mn(IV) oxides. Limited
epidemiological evidence for Cr(VI) ingestion is suggestive of elevated risks for stomach cancers. Exposure of animals to Cr(VI) in
drinkingwaterinducedtumorsinthealimentarytract,withlinearandsupralinearresponsesinthemousesmallintestine.Chromate,
thepredominantformofCr(VI)atneutralpH,istakenupbyallcellsthroughsulfatechannelsandisactivatednonenzymaticallyby
ubiquitously present ascorbate and small thiols. The most abundant form of DNA damage induced by Cr(VI) is Cr-DNA adducts,
which cause mutations and chromosomal breaks. Emerging evidence points to two-way interactions between DNA damage and
epigenetic changes that collectively determine the spectrum of genomic rearrangements and proﬁles of gene expression in tumors.
ExtensiveformationofDNAadducts,clearpositivityingenotoxicityassayswithhighpredictivevaluesforcarcinogenicity,theshape
of tumor dose responses in mice, and a biological signature of mutagenic carcinogens (multispecies, multisite, and trans-sex
tumorigenic potency) strongly support the importance of the DNA-reactive mutagenic mechanisms in carcinogenic eﬀects of
Cr(VI). Bioavailability results and kinetic considerations suggest that 10 20% of ingested low-dose Cr(VI) escapes human gastric
inactivation.Thedirectlymutagenicmodeofactionandtheincompletenessofgastricdetoxiﬁcationargueagainstathresholdinlow-
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serious cases of anthropogenic contamination of drinking water
in the U.S. came from the discharges of toxic Cr(VI) by cooling
towers.
4 Other large-scale environmental pollution with Cr(VI)
involved improper disposal of millions of tons of incompletely
processed chromite ore.
5 Hundreds of the largest toxic waste
sites in the U.S. known as Superfund sites contain Cr as a major
contaminant.
2ThepresenceofCr(VI)indrinkingwatercanalso
result from the oxidation of naturally occurring Cr(III) by
Mn(III/IV) oxides in birnessite,
6 a common mineral that coats
weathered grains and fractures in Cr-rich ultramaﬁc rocks and
serpentinites that are enrichedwith chromite [FeCr(III)2O4]. In
addition to birnessite, the presence of two other Mn(IV) oxide-
containing minerals, asbolane and lithiophorite, has also been
associated with the formation of Cr(VI) from natural Cr(III).
7
Examination of four minerals made of Mn oxides (birnessite,
cryptomelane, todorokite, and hausmannite) showed that bir-
nessitehadthehighestabilitytooxidizeCr(III)underlaboratory
conditions.
8
Cr(0)-containing products are generally highly resistant to
corrosion; however, slow oxidation of Cr-containing alloys can
resultinthe limitedrelease of soluble Cr(III) into soil and water.
Cr(VI) is the most mobile form of chromium in the environ-
ment. Mobility of Cr(III) strongly depends on the acidity and
Cr(III)-binding properties of soluble and insoluble components
at the contamination sites. Cr(VI) and Cr(III) have dramatically
diﬀerent toxicological properties,
1,2 and all public health con-
cerns are centered on the presence of toxic hexavalent Cr in
drinking water. In 1991, the US-EPA set the current standard for
Cr in drinking water (maximum contaminant level) at 100 μg/L,
9
which does not distinguish between the presence of toxic
Cr(VI) and nontoxic Cr(III). Considering long-standing public
concerns about Cr(VI), it is unclear why there are no require-
ments for speciﬁc monitoring of Cr(VI) levels. The analytical
technologies for Cr speciation and detection were not very sen-
sitive until the mid-1980s, and reliable measurements of Cr(VI)
atenvironmentallevelstypicallyrequiredpreconcentrationsteps,
which were more suitable for specialized academic laboratories
than for routine monitoring. However, analytical methodologies
for Cr(VI) underwent dramatic improvements a long time ago.
The EPA’s ownMethod 218.6 forthe detection of hexavalent Cr
was developed approximately 20 years ago and aﬀords a reliable
monitoring of Cr(VI) at 1 μg/L. This methodology is not
expensive and is based on a routine HPLC column separation
of chromate anion followed by a colorimetric detection with
diphenylcarbazide. Essentially all analytical laboratories are
equipped with HPLC and should be able to perform this type
of Cr(VI) measurements at relatively low cost. Recent improve-
mentsofchromatographicandpostcolumnderivatizationconditions
in the EPA’s Method 218.6 allow the detection of Cr(VI) in
drinking water at 3 ng/L (Application Update 179 from Dionex,
Inc.). This sensitivity is more than suﬃcient to meet the most
stringent regulations for Cr(VI), including those associated with
the Public Health Goal of 20 ng/L in California. For many
samples with very low Cr levels, Cr(VI) analyses by the modiﬁed
Method 218.6 could be even more sensitive than measurements of
total Cr. Although the presence of Cr(VI) near municipal water
reservoirs is the obvious reason for its monitoring in drinking water
supplies, environmental contamination with Cr(III) can also gen-
erate Cr(VI) through oxidation reactions with water chlorination
products,
10CaandMnoxides,
11,12 and photoxidation.
13Overall,
industrial activities associated with the direct release of Cr(VI)
into the soil and water is the most important source of Cr(VI)
contamination in drinking water (Figure 1).
2. MAIN AQUEOUS FORMS OF Cr(VI) AND Cr(III)
2.1. Chromium-3 Cr(III) forms hexacoordinate complexes
withtheoctahedralarrangementofligands.Hexaaquachromium-
(III) [Cr(H2O)6
3+] is the main Cr species in solutions of
inorganic Cr(III) salts under strongly acidic pH. At pH 4 and
higher,Cr(III)-boundH2Omoleculesundergohydrolysis,which
leads to the formation of soluble and insoluble oligomeric and
polymericproducts(Figure 2A). The reactions of hydrolysisand
polymerization are accelerated by increasing pH >5, and adjust-
ment of solutions to neutralpH results ina rapid precipitation of
multinuclear Cr(III) hydroxides. In addition to pH, the genera-
tion of polymeric products is influenced by the Cr concentra-
tions, composition, and “age” of the solutions. Surface waters
commonly contain a mixture of soluble monomeric and oligo-
meric Cr(III) products.
14,15 Mild acidity and the absence of
significant amounts of organics in drinking water supplies limit
the presence of dissolved Cr(III) due to its poor solubility. In
contrast to its aqua complexes, Cr(III) compounds with small
organicmoleculessuchasorganicacids,biologicalbuffers,amino
acids, and others are soluble and remain monomeric for a long
time.
16Thus,thedescriptionofCr(III)insolubilityatneutralpH
is only correct for solutions lacking ligands that compete with
H2O. Formation of stable Cr(III) complexes with small organic
molecules at the primary source of emission or contamination
sites can increase their environmental mobility and maintain the
solubilityofCr(III)evenatneutralpH.BindingofCr(III)byFe-
oxyhydroxides and immobilized organic matter in the soil or
sediments diminishes its soluble pool. Interactions between
Cr(III) with components of environmental media involve con-
tinuous cycles of adsorption/desorption and precipitation/dis-
solution, which control the extent of its environmental mobility.
Animal and epidemiological studies have consistently found
inorganic Cr(III) to be nontoxic and noncarcinogenic,
1,2 which
has also been conﬁrmed for the dietary supplement chromium
picolinate.
17 The absence of toxic eﬀects for Cr(III) complexes
results from their poor ability to enter cells, lack of intracellular
accumulation, and high stability of coordinated multidentate
ligands, which prevents binding to cellular macromolecules.
16
SystemicabsorptionofCr(III)takenbyhumanvolunteersinthe
form of dissolved inorganic salts is measurable but usually less
than 0.5%.
2,18 No elevation in urinary excretion of Cr(III) was
detected from the ingestion of insoluble Cr2O3,
19 which raises
the question as to why the use of inorganic salts resulted in
Cr(III) absorption at all considering the formation of oligomeric
products after the dissolution of these compounds in water.
Figure 1. Origin and interconversion of diﬀerent forms of Cr in water.
Route 1 isthe most important overall source ofCr(VI), whereas route 2
describes the most important natural process of Cr(VI) formation.1619 dx.doi.org/10.1021/tx200251t |Chem. Res. Toxicol. 2011, 24, 1617–1629
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A plausibleexplanationfor theseresultsliesinhighlyacidiccondi-
tions of the human gastric environment (pH 1 3),
20 which is
expected to promote dissociation of Cr(III) oligomers. Low pH
also strongly enhances the exchange of H2O for organic ligands
in the Cr(III) coordination sphere,
21 allowing the formation of
new Cr(III) complexes that could remain soluble upon reaching
neutral pH of the small intestine, where the absorption of metal
ions takes place. A short stomach residency time for pure water
and other simple liquids, however, is expected to limit the extent
of ligand exchange reactions.
2.2. Chromium-6. Chromate anion (CrO4
2 ) is the predo-
minant formofCr(VI) indilutesolutionsatneutralpH.Chromate
exists in equilibrium with its protonated form HCrO4
  in
approximately 3:1 ratio at these conditions.
22 HCrO4
  becomes
the most prevalent species of Cr(VI) at pH < 6. Concentrated
solutions of Cr(VI) at highly acidic pH contain the dichromate
anion Cr2O7
2  (Figure 2B). At levels below the current federal
standard of 100 μg/L, the presence of dichromate in drinking
water should be minimal. Both chromate and dichromate have
tetrahedral arrangements of coordinated oxygen groups.
Cr(VI) is a potent oxidant at highly acidic pH when any
organic molecule with oxidizable groups can promote its reduc-
tion to Cr(III). Increasing pH enhances the stability of Cr(VI),
particularly atnearneutralandalkaline pH. The strong pH eﬀect
onCr(VI)reduction isdemonstratedbytheﬁndingsthathuman
gastric juice was capable of reducing approximately 70% of
Cr(VI) after a 30-min incubation at pH 1.4 but was completely
ineﬀective at pH 7.0.
18 The presence of Fe
2+ is important for
abiotic reduction of Cr(VI) under anaerobic conditions in soil
and underground water. Uptake and reduction by microorganisms
isanotherdetoxiﬁcationprocessforCr(VI),althoughitislimitedby
the ability of resistant bacteria striving in contaminated water to
rapidly extrude Cr(VI).
23 Overall, Cr(VI) is a persistent contami-
nant in many water sources due to their low organic content and
lack of suﬃcient acidity to catalyze reduction to Cr(III).
3. CELLULAR METABOLISM AND DNA DAMAGE BY Cr(VI)
3.1. Cellular Metabolism. Cr(VI) displays no ability to
damage DNA directly and requires reductive activation for its
genotoxic activity.Structural similarityof chromateionto sulfate
(Figure 2B) allows its easy entry through the general sulfate
channels.
16Aswithabioticreactions,cellularreductionofCr(VI)
yields thermodynamically stable Cr(III).
24,25 Efficient uptake of
Cr(VI) followed by Cr(III) trapping via its binding to macro-
molecules leads to a massive accumulation of Cr relative to its
extracellularconcentrations,rangingfrom10-to20-foldafter3-h
exposures to about 100-fold after 24-h exposures.
26,27 With
the apparent exception of bacteria producing hyperoxidized
Mn(III/IV),
28 biological systems lack the ability to reoxidize
Cr(III)toCr(VI).ExtracellularreductionofCr(VI)isadetoxification
processthatproducespoorlypermeablenontoxicCr(III)(Figure3).
Studies of reduction activities in tissue homogenates and biolo-
gicalfluidsshowedthatascorbate(Asc)wastheprincipalbiological
Figure 3. Reduction of Cr(VI) and its genotoxic impact. Extracellular
reduction is a detoxiﬁcation process, generating poorly cell-permeable
Cr(III). In contrast, cellular Cr(VI) reduction is the activation process,
producing redox-active intermediates Cr(V/IV) and stable Cr(III)
forming mutagenic Cr-DNA adducts. Asc is the dominant reducer of
Cr(VI) in cells in vivo, whereas GSH is the most prominent reducer in
cultured cells due to their Asc-deﬁciency.
Figure 2. Aqueous species of Cr(III) and Cr(VI). (A) Hydrolysis and polymerization of hexaaquachromium(III). Transition pH values are
approximate. (B) Structures of sulfate, chromate, and dichromate.1620 dx.doi.org/10.1021/tx200251t |Chem. Res. Toxicol. 2011, 24, 1617–1629
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reducer of Cr(VI), accounting for 80 95% of its metabolism.
29 31
A combined activity of Asc and small thiols glutathione (GSH) and
cysteine is responsible for >95% of Cr(VI) reduction in vivo.T i s s u e
concentrations of GSH and Asc are not usually dramatically
different, and the predominant role of Asc stems from its very high
rate of Cr(VI) reduction. At physiological 1 mM concentration, t1/2
for Cr(VI) reduction by Asc was 1 min vs 60.7 min for GSH and
13.3minforCys.
32Despiteitsslowerrateofreduction,GSHismore
important for Cr(VI) metabolism than Cys due to its higher cellular
concentrations.
Depending on the nature of the reducing agent, its concentra-
tion, and stoichiometry, Cr(VI) reduction reactions generate
variable amounts of transient products such as Cr(V), Cr(IV),
andsulfur-andcarbon-basedradicals.
33 36Asexpectedforthese
important biological antioxidants, GSH-, cysteine-, and Asc-
derived radicals formed in Cr(VI) reactions are unreactive
toward DNA.
32,37,38 In the presence of H2O2, intermediate Cr
forms can catalyze Fenton-type reactions, generating highly
reactive OH￿ radicals.
39,40 Formation of reactive oxygen species
(ROS) and direct oxidizing abilities of Cr(V)
41,42 are the two
main processes contributing to the induction of oxidative stress
in Cr(VI)-treated cells. More detaileddiscussion of properties of
intermediate Cr forms can be found in other reviews.
43,44
Although all biological reducers convert Cr(VI) to Cr(III), their
mechanisms of reduction are not the same. Kinetic analyses
predict thatCysactsalmostexclusivelyasaone-electronreducer,
45
which is consistent with the presence of strong Cr(V) signal in
Cys-driven reactions.
46 Reduction by GSH can proceed through
either one- or two-electron reactions.
34,47,48 Asc is a highly
eﬃcient two-electron donor, yielding Cr(IV) as the ﬁrst reduc-
tion intermediate and dehydroascorbic acid as the oxidized
product. The presence of Cr(V) is only detectable under non-
physiological conditions of equimolar or higher ratio of Cr(VI)
to Asc.
35,49,50 Insuﬃcient amounts of Asc for the completion of
Cr(VI) reduction in these reactions were responsible for a
transient appearance of Cr(V), likely resulting from compropor-
tionation of Cr(IV) and Cr(VI). Severe Asc deﬁciency of human
and nonhepatic rodent cells in standard cultures
27,51 54 raises
concerns that studies with cultured cells may not accurately
recapitulate genotoxic properties of Cr(VI) in vivo. The Asc-
depleted state of cultured cells results from the absence of this
vitamin in the most common types of synthetic growth media,
and typical additions of 10% serum to the media theoretically
suppliesonly10%ofnormalvitaminClevels.Theactuallevelsof
Asc in the growth media are lower due to its loss during the
preparation and storage of serum. The half-life of Asc at 37 Ci n
cellculturemediais6 7h.
55Recentlyfedcellscancontainupto
50 60 μM vitamin C, but in many cases, its levels are drama-
tically lower or undetectable. Even when cells start with 50 
60 μM Asc, theybecomecompletelydepleted of Ascafter24 48 h
in culture.
54 Physiological concentrations of vitamin C in white
blood cells and epithelial tissues are usually in the 1 2m M
range.
55 57
3.2. Cr-DNA Damage. Cellular metabolism of Cr(VI) can
cause both oxidative and nonoxidative forms of DNA
damage.
43,44,58 The most abundant and specific type of DNA
damage is Cr-DNA binding (adducts), which has been detected
in reduction reactions in vitro, in various cultured cells and
in vivo.
16 Formation of Cr-DNA adducts in human cells was
already clearly evident after brief exposures to 2 μM (current
federal standard for Cr in water) and even lower concentrations
of Cr(VI).
27,59 The rapid loss of Cr-DNA adducts from normal
butnotnucleotideexcisionrepair(NER)-deficienthumancells
59
firmly demonstrated that Cr binding to chromosomal DNA
occurred in intact cells and did not arise artificially during
DNA purification. Cr-DNA adducts are a heterogeneous group
that includes binary [Cr(III)-DNA] and several ternary [ligand-
Cr(III)-DNA] adducts where the ligand can be Asc, GSH,
cysteine,orhistidine.Allfourternaryadductshavebeendetected
in Cr(VI)-treated cells
51,60 and are readily formed during in vitro
Cr(VI) metabolism. DNA cross-linking of GSH,
33,38,61 cysteine,
21
and Asc
32,51 was observed in their corresponding reactions with
Cr(VI), while DNA attachment of nonreducing amino acid
histidine occurred efficiently during the reduction of Cr(VI)
with Asc.
62 Cr(VI) also causes the formation of protein-Cr(III)-
DNA cross-links,
63,64 which are rare lesions and whose main
toxicological significance could lie not necessarily in the con-
tribution to genotoxic responses but rather in the inhibition of
gene-specific expression.
65 Binary Cr-DNA adducts are the most
frequent DNA modificationsinthe in vitro reductions of Cr(VI).
In Cr(VI) reactions with its two main biological reducers, Asc
51
and GSH,
38 binary adducts accounted for 75 95% of the total
DNA-bound Cr. When normalized for recovery, Asc-Cr-DNA
cross-links have been calculated to comprise 6% of Cr-DNA
adducts in human A549 cells with restored Asc levels.
51 Cys-Cr-
DNA and GSH-Cr-DNA accounted for 24 and 17% of all DNA
adducts in hamster CHO cells,
60 although these values have not
been adjusted for recovery.
Protein-Cr-DNA cross-links constitute only about 0.1% of
total adducts immediately after Cr(VI) exposures,
16,66 but their
relative amounts arelikelyhigher atlater postexposure times due
to delayed formation
67 and slower repair
66 relative to those of
small Cr-DNA adducts.
59 All small ternary adducts are formed
via the conjugation of preformed ligand-Cr(III) complexes with
DNA,
51,62 whereas protein DNA cross-linking proceeds through
the initial formation of binary Cr(III)-DNA adducts followed
by a slow reaction of protein capture.
67 Binary Cr(III)-DNA
adducts can result from direct DNA binding by Cr(III), but the
role of other Cr forms in their formation cannot be excluded.
16
3.3.MutagenicityofCr-DNAAdducts.Complexmetabolism
of Cr(VI) and the formation of several types of DNA damage
make it difficult to assess the importance of specific lesions in
Cr(VI)-treated cells. These difficulties can be overcome using a
shuttle-vector methodology, which allows for the examination of
mutagenic and genotoxic properties of in vitro formed DNA
damage during replication in intact human cells. Replication of
adduct-carrying shuttle-vectors in human cells showed that the
most abundant adduct, the binary Cr-DNA conjugate, was
weakly mutagenic, whereas four ternary adducts containing
DNA-cross-linked Asc,
32 GSH, cysteine, and histidine
68 were
strongly mutagenic. Asc-Cr-DNA was the most potent muta-
genic and replication-inhibiting adduct. In vitro reduction of
Cr(VI) by purified Asc,
32 GSH,
38 or cysteine
37 also led to the
production of mutagenic and replication-blocking DNA lesions,
as revealed by analyses of replicated progeny of shuttle-vector
plasmids propagated in human fibroblasts. Asc-driven metabo-
lism of Cr(VI) in vitro resulted in the strongest mutagenic
responses,
32 while reactions with GSH showed low yields of
mutagenic damage and GSH-Cr-DNA adducts.
38 These findings
were corroborated by a strong potentiation of Cr(VI) mutageni-
city in cells with restored Asc levels.
27 Blocking of Cr-DNA
binding during the reduction or dissociation of Cr-DNA adducts
eliminated all mutagenic and replication-blocking responses in
shuttle-vectorplasmidsincubatedinCr(VI)reactionscontaining1621 dx.doi.org/10.1021/tx200251t |Chem. Res. Toxicol. 2011, 24, 1617–1629
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Asc,
32,69 GSH,
38 or Cys,
37 demonstrating a key role of Cr-DNA
adducts in the mutagenicity and genotoxicity of Cr(VI) when
metabolized by its three main biological reducers. In agreement
with these results, in vitro reduction reactions employing iron-
free reagents failed to generate detectable amounts of single-
strand breaks and abasic sites in DNA.
21,32,38,45 Inhibition of in
vitro replication on DNA templates damaged in Cr(VI)-Asc
reactions was also dependent on Cr-DNA binding.
70
Involvement of Cr-DNA adducts in bacterial mutagenesis by
Cr(VI)isindicatedbyhigheryieldsofrevertantsintheAmestest
using a NER-deﬁcient Salmonella uvrA strain.
71 Cr(VI) muta-
genicity in transgenic lacI mice was inhibited by GSH depletion,
72
whichpointstotheimportanceofnonoxidativemechanismsand
GSH-Cr-DNA adducts in mutagenic responses in vivo. Cr(VI)-
induced fold changes in the number of HPRT mutants were
reported to be lower in NER-deﬁcient clones of CHO cells grown
under the standard Asc-deﬁcient conditions,
73 which contrasts
thepositiveroleofNERintheremovalofadductsandsurvivalof
CHO
74andhumancells.
59Thus,itispossiblethatNERoperates
diﬀerentlyondistinctCr-DNAadducts.However,interpretation
of the results with NER-null CHO clones was complicated by
their greater background mutation frequencies, and these high
denominator values oﬀer an alternative explanation for an
appearance of diminished mutagenic responses for Cr(VI) when
data were expressed as a fold of change.
73
3.4. Chromosomal Breakage by Cr-DNA Adducts. Ternary
but not binary Cr-DNA adducts were strong inhibitors of
replication in plasmids transfected into human cells.
32,37 These
results were unexpected given weak structural distortions in Cr-
adducted DNA with 1 2 unwinding angle per Cr atom
75 and
the inability of Cr-DNA adducts to block DNA replication in
vitro.
61,70ThephosphategroupisaprimarysiteforCr(III)-DNA
binding,
62,68 although additional coordination to N7-dG is also
possible as evidenced by the ability of Cr(III) to bind to dG,
62
G/C-targeted mutagenesis
32,37,68 and preferential incisions by a
bacterial NER nuclease in Cr-adducted DNA.
76 Replication
inhibition by ternary Cr-DNA adducts required the presence of
mismatchrepair(MMR)proteins,
77whichwerefoundtorecognize
these modifications with an affinity that was comparable to that
of their natural substrate, G/T mismatch.
78 Binary Cr-DNA
adducts were poorly bound by MMR proteins, and their weak
effects on vector replication were MMR-independent.
78 In a full
agreement with plasmid replication experiments, MMR-null
mouse and human cells were resistant to apoptosis and clono-
genic toxicity by Cr(VI).
52,77,78 Studies with human cells of
different histological origin showed that the high genotoxicity
and cytotoxicity of Cr-DNA adducts resulted from their mis-
processingbyMMRintoDNAdouble-strandbreaks(DSB).
27,77,78
Importantly,DSBweredetectedbyvarioustechniques,including
a direct methodology of pulse-field gel electrophoresis.
78 MMR
was responsible for all DSB generated in Asc-restored normal
humancellstreatedwithbothhighandverylowenvironmentally
relevant (0.2 2 μM) concentrations of Cr(VI).
27 The Asc-Cr-
DNAadductwasveryefficientlyrecognizedbyMMRproteinsin
vitro,
78 and restoration of Asc levels in cells strongly increased
cytotoxicityandDSBformationbyCr(VI)viaMMRactivity.
27,52,78
Asc-deficiencyofhumanlungBEAS-2Bcellsduringtheirchronic
exposures to Cr(VI) could explain the inability of this cell
transformation model
79 to recapitulate a hallmark of Cr(VI) car-
cinogenesis in the lung, microsatellite instability resulting from
inactive MMR.
58
FormationofDSBbyCr-DNAadductsoccursintheG2phase
ofthecellcycle,
27,77,78althoughtheirinitialrecognitionbyMMR
proteinstakesplaceintheprecedingSphaseandisdependenton
ongoingreplication.
27,78G2-speciﬁcDSBwereobservedforboth
soluble
27,77 and particulate chromates.
80 A progression of G2
cells with incompletely repaired DNA breaks through the cell
cycle could be responsible for the observed S-phase arrest and
DSB during chronic exposures to Cr(VI).
81,82 Cr-induced DSB
weremorepersistentinhumancellslackingWRNhelicase,
82,83a
protein mutated in the Werner syndrome of premature aging.
WRN was speciﬁcally required for the repair of MMR-generated
DSB through its involvement in the activation of the initial steps
in homologous recombination, leading to the formation of
RAD51 foci.
83 Cr(VI) treatments of WRN-deﬁcient cells also
led to higher levels of telomere damage,
84 although it remains
unknown whether Cr-DNA adducts and aberrant MMR con-
tribute to the observed telomeric abnormalities.
4. CARCINOGENICITY OF Cr(VI) VIA DRINKING WATER
4.1. Epidemiological Studies. Occupational exposures to
Cr(VI) via inhalation have consistently been found to increase
the risk of cancers in the respiratory system. Both highly soluble
and poorly soluble chromates were determined to be carcino-
genic.
1,2,85 87 Information about the carcinogenicity of ingested
Cr(VI) is much more limited. A study by Zhang and Li
88
reported increased mortality from stomach cancers among rural
residentsintheLiaoningProvinceofChinawheredrinkingwater
was heavily contaminated with Cr(VI) released by the ore
smelting facility. One recent reanalysis of this study confirmed
the originally reported association between Cr(VI) contamina-
tion and cancer mortality,
89 while another study using a smaller
control population did not.
90 A meta-analysis of studies among
chromate workers did not find a link between inhalation ex-
posures to Cr(VI) and cancers outside the respiratory system.
91
Neither the ecological report from China nor the meta-study of
occupational exposures is strong in addressing the issue of
Cr(VI) carcinogenicity in the digestive system. Inherent to all
ecologicalstudiesistheirinabilitytocontrolforconfoundersand
other risk factors, which is important for the analysis of stomach
tumors in China with its well-known high incidence of this
cancer. For human inhalation exposures, Cr(VI) ingestion was
only assumed, and even if it occurred, ingested doses of Cr(VI)
wouldbedramaticallylowerthandosesintherespiratorytissues.
Therefore, susceptible individuals would be expected to develop
lethal lung cancers before the appearance of the late age-arising
tumors in the GI system. Tobacco smoking is a risk factor for
cancers in many tissues, and very high percentages of smokers in
theindustrialcohortswouldfurtherdiminishtheabilitytodetect
any moderate carcinogenic effects of airborne Cr(VI) in the
alimentary tract.
4.2. Animal Studies. The National Toxicology Program
(NTP) has recently completed 2-year rodent studies of Cr(VI)
carcinogenicity via drinking water exposure.
92 Both male and
female F344/N rats showed significantly increased incidence of
tumors in the oral cavity at the highest concentration of Cr(VI)
(180 mg/L). B6C3F1 mice of both sexes developed tumors in
the small intestine (duodenum and jejunum), with statistically
significant increases at the two highest doses of Cr(VI). Plots of
mousetumor rates versusdailyingesteddosesof Cr(VI) showed
a linear shape of dose dependence for males and supralinearity
for females (Figure 4A). The duodenum of all exposed mice had1622 dx.doi.org/10.1021/tx200251t |Chem. Res. Toxicol. 2011, 24, 1617–1629
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elevated incidences of diffuse epithelial hyperplasia, which was
graded from minimal to mild. No overt toxicity (necrosis) was
found in the small intestine of any Cr(VI)-exposed groups of
mice or rats.
Cr(VI) ingestion intheNTPstudy
92hasalsoledtosomepro-
inﬂammatory responses detected by the presence of the inﬁltrat-
inghistiocytes.Signiﬁcantincreasesinhistiocyticcellinﬁltrations
were foundintheupperportionofthesmallintestine(duodenum)
andmesentericlymphnodesinbothsexesofmiceandratsandin
the liver of male and female rats and female mice. The pancreatic
lymph nodes of female rats and male and female mice also had
elevated amounts of histiocytic inﬁltrates. It has been recently
hypothesizedthatinﬂammationandtheresultingoxidativeDNA
damage could be important factors in the carcinogenic eﬀects of
ingested Cr(VI).
93,94 However, the presence of histiocytic inﬁl-
trations at several sites in rats was not associated with Cr(VI)
carcinogenesis in this species. In mice, the overlap between the
appearance of histiocytic cells and tumorigenesis was found only
in the small intestine but not in the liver or lymph nodes. The
biological signiﬁcance of histiocytic inﬁltrations and their ability
to cause oxidative DNA damage in the host tissue cells are
currently unknown.
Arecentstudyutilizing5and20mg/LCr(VI),concentrations
that were below carcinogenic doses inthe NTProdentassay, did
not ﬁnd any increases in two forms of DNA damage in the
duodenum of female SKH-1 mice after 9-month long exposure
through drinking water.
95 These results were viewed as suppor-
tive of the threshold mechanism, questioning the human rele-
vance of the observed carcinogenic eﬀects in the mouse small
intestine. However, the employed biomarkers were insensitive
forthedetectionofDNAdamageinthemouseduodenum.After
a massive ex vivo exposure to 1.6 mM Cr(VI) (83.2 mg/L), only
2.5- and 3.8-fold increases were measured for protein DNA
cross-linksand8-oxo-dG,respectfully.Suchalowresponsiveness
wasclearlyinsuﬃcienttodetectDNAdamageforexposureswith
4.2- and 16.6-times lower Cr(VI) levels in the 20 mg/L and 5
mg/L test groups,even in the implausible situation of no reduction
andnodilutionofCr(VI)inthestomach.Theuseof8-oxo-dGas
a biomarker of DNA damage has one severe limitation: its short
lifetime. Repair of 50% 8-oxo-dG occurs within 30 min and is
completeby2h.
96Thisshortlifetimewouldmakeitverydiﬃcult
to detect 8-oxo-dG even after recently ingested water with a
suﬃciently high dose producing strong responses ex vivo.
4.3.IsCytotoxicity-DrivenProliferationInvolvedinMouse
Intestinal Carcinogenesis? The presence of diffuse epithelial
hyperplasia in the duodenum of mice could raise the question of
whethertumorigenesisinthistissuewasahigh-doseeffectresulting
from Cr(VI) cytotoxicity and subsequent compensatory prolif-
eration. Although the NTP study has not found evidence of
necrosis in the small intestine of Cr(VI)-exposed mice,
92 it is
possible that the diffuse hyperplasia was a result of regenerative
responses. Persistent hyperproliferation could lead to increased
accumulation of spontaneous mutations and eventually cancer.
This carcinogenic process should exhibit a steep sublinear,
threshold-type dose dependence (Figure 4B), as it relies on the
inductionofcelldeath,andsmallnontoxicdoseswouldbeunable
to initiate tumorigenesis.
The presence of Cr(VI)-induced hyperplasia could also be
viewed as a manifestation of cancer-protective responses by the
small intestine. Elimination of genetically damaged cells by
apoptosis or another form of cell death is a ﬁrmly established
protectivemechanismagainstcancer.Thus,therearetwoopposing
interpretations for the carcinogenic signiﬁcance of the diﬀuse
epithelial hyperplasia: one is pro-tumorigenic; the other is anti-
tumorigenic.Thesupralinearshapesofdose tumorresponsesin
the NTPstudies forfemale mice and combined male plus female
results (Figure 4A) are more consistent with the activation of
cancer-protective mechanisms. Tumor rates versus dose in male
mice visually displayed a linear dose-dependence. Thus, experi-
mental results do not support the engagement of cytotoxicity-
based carcinogenic mechanisms with their expected dose 
response sublinearity.
4.4. Cocarcinogenicity of Cr(VI). The presence of Cr(VI) in
drinking water has been found to increase the frequency of skin
tumors in UV-irradiated hairless mice.
97,98 Ingestion of Cr(VI)
aloneproducednoskintumors,indicatingthatsynergisticeffects
resulted from the enhancement of UV-initiated tumorigenesis.
Cocarcinogenic activity of Cr(VI) did not involve oxidative
mechanisms, as supplementation with antioxidants vitamin E
or selenomethionine showed no effect on its potentiating ability.
98
These two antioxidants effectively suppressed the ability of
As(III) to enhance UV skin carcinogenesis in hairless mice.
99
ApossibletargetforsynergismbetweenCr(VI)andUVcouldbe
the repair of DNA photolesions by NER. Since abundant Cr-
DNA adducts are good NER substrates,
59 they would compete
with UV-DNA damage for NER proteins and consequently
increase the persistence of premutagenic pyrimidine dimers in
UV-irradiated keratinocytes. The biological plausibility of Cr UV
cocarcinogenesis through the competition for NER factors is
supported by the comutagenicity of Cr(VI) and UV.
100
4.5. Critical Factors for Low-Dose Extrapolation. As i n g l e
ecological study linking the presence of high Cr(VI) concentra-
tionsindrinkingwatertoelevatedmortalityfromstomachcancers
didnotincludeadose-dependenceanalysis,
88makingitunsuitable
for risk assessment. Therefore, calculations of cancer risks from
Cr(VI) ingestion must rely on the extrapolation of results from
high-dose animal studies to low-dose human exposures. This
situation is very common, as potential environmental exposures
to carcinogens are always much lower than doses in positive
epidemiological or animal studies. The use of high carcinogen
doses in the NTP bioassay results from the need to obtain
statistically robust tumor responses. As an illustration of this
problem, the standard size of 50 animals/group was insufficient
to reach statistical significance for a 4-fold increase in the tumor
rate for female mice receiving 1.2 mg/kg daily Cr(VI) dose.
92
Figure4. (A)Tumorratesinthesmallintestineofmiceasafunctionof
ingested daily dose of Cr(VI). Data are from the NTP bioassay.
92 (B)
Expected shape of tumor dose-dependence for a carcinogenic mechan-
ism based on cytotoxicity-induced regenerative proliferation.1623 dx.doi.org/10.1021/tx200251t |Chem. Res. Toxicol. 2011, 24, 1617–1629
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A linear extrapolation of cancer risk to low environmental
doses is a default regulatory approach for carcinogens with a
mutagenic mode of action via DNA-reactive mechanisms.
101 A
second critical consideration for linear extrapolations is whether
environmental levels are suﬃcient to deliver a parental carcino-
gen or its reactive metabolite to a target organ. In the case of
Cr(VI), the question of environmental relevance of the high-
dose animal results is centered on the completeness of Cr(VI)
reductive inactivation in the human stomach prior to reaching
thesmallintestine.Thenexttwosectionswillreviewevidencefor
Cr(VI) mutagenicity/genotoxicity and incompleteness of gastric
reduction at low doses.
5. MUTAGENIC MECHANISM IN Cr(VI)
CARCINOGENESIS
5.1. Mutagenicity of Cr(VI). Cr(VI) compounds have been
examined for mutagenicity in a large number of genotoxicity
assays, from bacteria to laboratory rodents and human cells.
Consistently positive results have been found in all standard
mutagenicity tests,
102 including a reverse mutation assay in
Salmonella,
1,71,103 HPRT mutagenesis in hamster V79 and
CHO cells,
104 TK mutagenesis in human lymphoma cells,
105
and in vivo assays in transgenic animals.
72,106 Cr(VI) is also
known to induce clastogenic micronuclei in primary human
cells,
27 chromosomal aberrations in various cell lines, and micro-
nucleiinvivo.
102MutagenicresponsesinstandardculturesofV79
and CHO cells were relatively moderate.
104 However, the
mutagenicity of Cr(VI) in CHO and V79 cells was dramatically
increased when their Asc levels were restored to physiological
levels.
27 Slowly dividing kidney and lung cells of lacI transgenic
mice
72 showed mutagenic responses to Cr(VI) that were com-
parable or even higher than those in rapidly dividing Asc-
deficient rodent cells,
104 further pointing to the limitations of
standard cellcultures toaccuratelyrecapitulategenotoxic effects.
A high frequency of deletions in plasmids treated with Cr(VI)
and Asc in vitro
32 and a poor recovery of deletion mutants at the
HPRT gene in cultured cells and lacI gene in transgenic mice
suggest that current in vivo models and Asc-restored cells could
still underestimate the true levels of Cr(VI) mutagenesis. In vivo
and in vitro mutagenicity tests are also incapable of detecting
chromosomal translocations, which are expected to arise from a
massive formation of Cr(VI)-induced DSB in Asc-normalized
cells.
27,78 Importantly, chromosomal translocations are a major
mechanism for the activation of oncogenes in human cancers.
107
Predictive values for rodent carcinogenicity are approximately
80% for the Ames test (reverse mutagenesis in Salmonella)
108
andevenhigherformutationassaysintransgenicrodents.
109The
micronucleus assay has lower predictive potential but it is
complementary to Ames and in vivo mutagenesis due to its
sensitivity in detecting deletion- and translocation-promoting
DSB. A recent analysis of a large database of carcinogenicity and
genotoxicity studies concluded that a combination of the Ames
test and the in vitro micronucleus assay was able to predict all
genotoxicrodentcarcinogens.
110Thus,thepositiveﬁndingswith
Cr(VI) in Ames, rodent mutation, and clastogenic micronucleus
assays discussed above strongly argue for the importance of a
mutagenic (genotoxic) mechanism in Cr(VI) carcinogenicity. A
general property of mutagenic chemicals is their multispecies,
trans-sex, and multisite carcinogenesis.
101 Cr(VI) clearly ﬁts this
description of a mutagenic carcinogen as it is known to induce
tumors in humans (unquestionably in the respiratory system),
laboratory rodents, both sexes of mice and rats, and at diﬀerent
locations (the muscular system and diﬀerent sites in the alimen-
tary canal and respiratory tract).
1,58,92
5.2. DNA-Reactive Mechanism in Cr(VI) Mutagenesis and
Clastogenesis. Mutagenic responses can arise from direct
chemical-DNA damage (DNA-reactive mechanism) or high
dose-induced nucleotide misbalances, reactive oxygen species,
and other metabolic alterations (indirect mutagenicity). Linear
low-dose extrapolations in cancer risk assessment are only
appropriate for DNA-reactive carcinogens.
101 Positive results
in the Ames test are considered as evidence of direct mutageni-
city, and they alone would represent a very difficult barrier to
overcome during a regulatory process for drug approval.
111 The
Ames test was consistently positive for Cr(VI)
1,71,103 but nega-
tive for noncarcinogenic Cr(III) compounds.
112,113 As discussed
in section 3.2 and summarized in earlier reviews,
16,114 Cr(VI)
causes extensive formation of Cr-DNA adducts in both in vivo
andinavarietyofhumanandrodentcellsinculture.TernaryCr-
DNA adducts were the principal mutagenic lesions generated
during Cr(VI) metabolism by its three main reducers.
32,37,38,69
Generationof DSB and chromosomal breaks by Cr(VI) was also
dependent on ternary Cr-DNA adducts that are mistakenly
recognized by MMR proteins as DNA mismatches and are then
processed into DNA breaks.
77,78 Importantly, Cr-DNA adducts
and MMR-dependent DSB were detected at environmentally
relevant doses both at and below the current federal standard for
Cr in drinking water.
27 Collectively, these results demonstrate
thatDNA-reactiveprocessesinvolvingtheformationofCr-DNA
adducts are major causes of Cr(VI) mutagenesis and clastogen-
esis. As argued earlier,
16 DNA binding by Cr(III) complexes
predicts a linear dose-dependence between cellular Cr(VI) and
mutagenic Cr-DNAadducts. Anyoxidativeor other forms ofCr-
DNA damage arising from reactions of Cr(IV) should also
display linear yields, as this intermediate is formed in all meta-
bolic reactions of Cr(VI) (Figure 3).
5.3. Genotoxic vs Epigenetic Mechanisms. Cancer is a
genetic disease caused by a combination of mutations activating
oncogenes and inactivating tumor suppressor genes. Recent
whole genome sequencing studies have found that human
tumors contain between several dozens and several hundreds
of cancer-promoting mutations.
115,116 Cancer can also be de-
scribed as an epigenetic disease since some tumor suppressor
genesaresilencedepigenetically,andcancercellsdisplayglobally
different gene expression profiles that require corresponding
chromatin remodeling at numerous promoters. Mutations in
only two cancer genes, the p53 tumor suppressor and the KRAS
oncogene, were sufficient to alter the expression of several
hundredgenes.
117Mutationsandothergenomicrearrangements
of histone-modifying proteins can convert them into oncogenes
with ensuing abnormal chromatin remodeling.
118 120 TET1 has
recently beenfoundtoparticipateinCpG demethylation,
121and
this gene forms a leukemia-inducing fusion product with the
MLL oncogene.
122 The opposite process of epigenetic changes
causing mutations can also take place. For example, biallelic
silencing of the MMR gene MLH1 via promoter hypermethyla-
tiondramaticallyincreasesmutationratesandeventuallyleadsto
colon cancer.
123
Approximately 80% of lung cancers among chromate workers
exhibitedmicrosatelliteinstability(ahallmarkofinactiveMMR),
which was associated with the loss of expression of key
MMR proteins.
124,125 This MMR-null phenotype was suggested
to result from the selection of resistant cells during chronic1624 dx.doi.org/10.1021/tx200251t |Chem. Res. Toxicol. 2011, 24, 1617–1629
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exposures to cytotoxic doses of Cr(VI), as MMR-deﬁcient cells
are resistant to killing by Cr(VI).
77 Epigenetic repression of
several genes (MLH1, p16, APC, and MGMT) in human
chromate-associated cancers
125 127 may reﬂect the presence of
mutations in proteins regulating epigenetic stability or a direct
ability of Cr(VI) to induce stable transcriptional silencing.
InductionofepigeneticeﬀectsbyCr(VI)hasbeendemonstrated
but onlyinAsc-deﬁcientcells.
128,129 Sunet al.
129 have found that
Asc supplementation blocked the induction of epigenetic
changes by chromate in human A549 cells. The importance of
Asc in epigenetic regulation stems from its role as a cofactor for
dioxygenases, a group of enzymes that include histone demethy-
lases and the 5mC demethylating protein TET1. Depletion of
cellularAscduringCr(VI) metabolismisexpectedtoimpedethe
removal of repressive DNA (methylated CpG) and histone H3
(Lys-9 di- and trimethylation) marks with the ensuing negative
consequences for gene expression.
Although DNA damage and epigenetic responses are com-
monly viewed as separate events, DNA repair can induce large-
scale chromatin remodeling, particularly in the case of DSB
processedbyhomologousrecombination.
130DSBhavealsobeen
shown to generate a rapid transcriptional repression in the
adjacent regions,
131 and it is possible that this repressive chro-
matin state can sometimes be retained even after the completion
of DSB repair. Cr(VI) is a potent inducer of DSB even at low
doses,
27,78 which could lead to the formation of transcriptionally
repressed sites.
6. IS HUMAN GASTRIC DETOXIFICATION OF LOW
Cr(VI) DOSES COMPLETE?
The carcinogenic risk of ingested Cr(VI) at environmentally
relevantdoseshasbeenquestioned
94onthebasisofthereported
high Cr(VI)-reducing capacity of gastric juice.
132,133 High detox-
iﬁcation potential of human stomach and other tissues is also a
key element of the threshold model of Cr(VI) carcinogenesis.
134
Thismodelwouldarguethatdespiteamutagenicmodeofaction,
the complete detoxiﬁcation of moderate Cr(VI) doses in the
stomach makes it inappropriate to perform linear extrapolations
of cancer risks from animal tumor responses detected at high
dosesthatcouldhaveexceededthecapacityforgastricreduction.
The ability of gastric juices to reduce/detoxify Cr(VI) is
generally accepted in the ﬁeld; however, studies with human
volunteers and kinetic considerations of reduction and stomach
emptyingtimedonotsupportthecompletenessofthedetoxiﬁcation
process.ThreefactorsinﬂuencetheextentofCr(VI)reductionin
the stomach: its reduction capacity, reduction rate, and stomach
emptying time. On the basis of the reported high reduction
capacity of the stomach (>80 mg/day),
133 the rate of reduction
by gastric juice under fasting conditions could exhibit pseudo
ﬁrst-order kinetics in a broad range of low to moderate Cr(VI)
concentrations.Afundamentalpropertyofﬁrst-orderreactionsis
independence of the reaction half-time on concentration. This
means thatthe extent of gastric reduction should bethe samefor
both very small and very large amounts of Cr(VI). In agreement
with ﬁrst-order kinetics, the initial rates of reduction by human
gastric juice were found to be independent of Cr(VI)
concentrations.
94,132 Reduction of 0.1 mg/L Cr(VI) (current
EPA standard for total chromium) by artiﬁcial gastric juice was
the ﬁrst-order reaction.
135 A similar bioavailability of Cr(VI) for
small and large doses further supports the ﬁrst-order reaction
kinetics of gastric reduction. For example, human subjects
excreted 2.1% of the ingested 20 ng of Cr(VI) in the 24-h
urine
18 and 1.43% of the ingested 5 mg of Cr(VI). The latter
value is my very conservative estimate calculated as 1/4th of the
average4-dayexcretionof 5.7% reported inthe original study.
136
Thus, the bioavailability of 20 ng and 5 mg of Cr(VI) (250,000-
foldrange)appearstobecomparable.Theapproximately10-fold
higher bioavailability of ingested Cr(VI) compared to that of
Cr(VI) reduced with orange juice prior to ingestion
137 suggests
that the bulk of absorbed Cr from Cr(VI) was likely a cell-
permeable chromate.
A classic study by Donaldson and Barreras
18 also performed a
very important experiment on the bioavailability of 20 ng of
Cr(VI) that was directly delivered into the duodenum of human
subjects.Inthiscase,10.6%ofCrwasexcretedintheurineversus
2.1% for ingestion. Since the duodenal delivery used 100%
Cr(VI), then the amount of Cr(VI) reaching the small intestine
in their oral route experiment can be derived from the urinary
excretion of 2.1% divided by 0.106 = 19.8%. For the study with
the ingestion of 5 mg of Cr(VI) by human volunteers,
136 the
sametypeofcalculationsusingtheestimated1.43%urinaryexcretion
predict 13.5% nonreduced Cr(VI) reaching the duodenum.
A second approach for the estimation of the percentage of
Cr(VI) escaping stomach detoxiﬁcation can be based on the
considerations of the competing processes of stomach emptying
and gastric reduction. Incubation with human gastric juice for
30minatroomtemperatureleft29.6%nonreducedCr(VI)based
on the diminished uptake by everted intestinal rings and 29.2%
from a chromatographic proﬁle (as determined by Image J).
18
Figure 5. Genotoxic risks of ingested Cr(VI). Dose-independence of gastric detoxiﬁcation is predicted to be applicable for a broad range of
environmental Cr(VI) concentrations. A linear yield of Cr-DNA adducts and chromosomal breaks at environmental Cr(VI) doses has been
demonstrated experimentally (section 5.2). Linearity of cancer risk at low levels of DNA damage is a default regulatory assumption for mutagenic
carcinogens.
101AtlowdosesofCr(VI),Cr-DNAadductsareaprincipalcauseofchromosomalbreaksinAsc-restoredhumancellsandmutagenicDNA
damageduringCr(VI)metabolismbyitsthreemainreducers.SublinearityofdirectandROS-mediatedDNAdamagebyCr(V)stemsfromitsdetectable
formation only under conditions of limited (depleted) Asc concentrations.1625 dx.doi.org/10.1021/tx200251t |Chem. Res. Toxicol. 2011, 24, 1617–1629
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The mean value of two measurements gives a rate with t1/2 =
17 min, which should be twice as fast at physiological tempera-
ture (t1/2 = 8.5 min) due to a typical increase in the reactions
rates by a factor of 2 for each 10 C increase. A review by
Paustenbach et al.
138 reported t1/2 = 7 min for the Cr(VI)
reduction rate by human gastric juice at physiological tempera-
ture. A combination of t1/2 = 15.2 min for human stomach
emptying(meanvaluefromthreestudieswithwater)
139 141and
a more protective rate of t1/2 = 7minpredicts that 22.2% Cr(VI)
willreachtheduodenum.Overall,bothbioavailabilityandgastric
reduction rate-based estimations suggest that 10 20% Cr(VI)
ingested with water escapes gastric inactivation and reaches the
small intestine, which is a site for its systemic absorption and a
target of carcinogenic eﬀects in mice. These estimates do not
apply to the consumption of water with food, which is expected
to promote Cr(VI) reduction through increased stomach resi-
dency time and delivery of additional reducers. Vitamin C-rich
products are particularly beneﬁcial for the enhancement of
gastric detoxiﬁcation of Cr(VI).
7. CONCLUSIONS
The presence of Cr(VI) in drinking water results from both
anthropogenic and natural sources. Limited epidemiological
studies are insuﬃcient to establish carcinogenic risks of Cr(VI)
ingestion in humans. Consumption of Cr(VI) through drinking
water produced clear carcinogenic eﬀects in both sexes of mice
and rats, and Cr(VI) has a ﬁrmly established potential to cause
human respiratory cancers. Since Cr(VI) is taken up via ubiqui-
tously expressed transporters and metabolized by ubiquitously
present cellular reducers, cells of the human digestive system are
also expected to form cancer-promoting Cr-DNA damage.
Multispecies and multisite carcinogenicity of Cr(VI) along with
its broad genotoxicity provide a strong basis for a classiﬁcation
of Cr(VI) exposures through drinking water as likely to be
carcinogenic to humans. Diverse lines of evidence demonstrate
the importance of a DNA-reactive mutagenic mechanism in
Cr(VI) carcinogenicity, lending mechanistic support for a linear
low-dose extrapolation of cancer risks in humans. The bioavail-
ability results and kinetic considerations indicate incomplete
gastric detoxiﬁcation of Cr(VI) at environmental levels of
exposure, predicting its uptake and genotoxic metabolism in
the small intestine (Figure 5).
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